Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 1.8% – Here’s Why

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares shot up 1.8% during trading on Wednesday . The company traded as high as $0.24 and last traded at $0.23. 22,176,383 shares changed hands during trading, a decline of 65% from the average session volume of 62,975,301 shares. The stock had previously closed at $0.23.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a report on Friday. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

The company’s 50 day moving average price is $0.26 and its 200 day moving average price is $0.31. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $44.01 million, a price-to-earnings ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, equities research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.